Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Share-based Compensation: 2014-2025

Historic Share-based Compensation for KalVista Pharmaceuticals (KALV) over the last 8 years, with Apr 2025 value amounting to $3.6 million.

  • KalVista Pharmaceuticals' Share-based Compensation fell 71.42% to $3.6 million in Q2 2025 from the same period last year, while for Apr 2025 it was $22.4 million, marking a year-over-year increase of 2.32%. This contributed to the annual value of $12.3 million for FY2025, which is 43.92% down from last year.
  • According to the latest figures from Q2 2025, KalVista Pharmaceuticals' Share-based Compensation is $3.6 million, which was up 21.44% from $3.0 million recorded in Q4 2024.
  • In the past 5 years, KalVista Pharmaceuticals' Share-based Compensation registered a high of $12.7 million during Q2 2024, and its lowest value of $2.7 million during Q1 2024.
  • In the last 3 years, KalVista Pharmaceuticals' Share-based Compensation had a median value of $3.2 million in 2023 and averaged $4.5 million.
  • Data for KalVista Pharmaceuticals' Share-based Compensation shows a maximum YoY slumped of 71.42% (in 2025) over the last 5 years.
  • KalVista Pharmaceuticals' Share-based Compensation (Quarterly) stood at $3.2 million in 2023, then dropped by 6.49% to $3.0 million in 2024, then tumbled by 71.42% to $3.6 million in 2025.
  • Its Share-based Compensation was $3.6 million in Q2 2025, compared to $3.0 million in Q4 2024 and $3.0 million in Q3 2024.